Mantle Cell Lymphoma | Tumor

CURE’s mantle cell lymphoma (MCL) page features the latest cancer news and updates on mantle cell lymphoma Through articles, videos, podcasts, and more, CURE brings readers the insights of experts, cancer survivors, patients, and advocates to ensure everyone is up to date in mantle cell lymphoma.

Managing Mantle Cell Lymphoma (MCL) after Relapsed on First Treatment

An interview with Dr. Luhua (Michael) Wang, MD, Department of Lymphoma and Myeloma, Division of Cancer Medicine, MD Anderson Cancer Center

Keep Inspiring

Don’t let your disease define you

Pharma Companies Pull Imbruvica Indication for Marginal Zone and Mantle Cell Lymphoma

April 7th 2023, 9:00pm

Article

Long-term data showed that the addition of Imbruvica did not improve overall survival in patients with marginal zone lymphoma or mantle cell lymphoma.

FDA Approvals From Winter 2023 You May Have Missed

March 21st 2023, 3:00pm

Article

Here’s a look back at the cancer drugs that gained FDA approval in the winter of 2023.

Jaypirca FDA Approval a 'Major Breakthrough' for Mantle Cell Lymphoma

February 21st 2023, 8:00pm

Article

An expert discusses the value of Jaypirca’s recent accelerated FDA approval for relapsed/refractory mantle cell lymphoma, as well as where treatment may go next.

FDA Approves Jaypirca for Relapsed/Refractory Mantle Cell Lymphoma

January 27th 2023, 8:10pm

Article

The Food and Drug Administration approved Jaypirca for patients with relapsed/refractory mantle cell lymphoma who have been previously treated with multiple lines of therapy.

Avoiding Unavoidable Carcinogens

January 4th 2023, 4:00pm

Article

We need to learn more about how to potentially lessen toxins' effects on people's lives.

Patients With Mantle Cell Lymphoma Continue to Respond to Tecartus Three Years Later

June 22nd 2022, 1:00pm

Article

Long-term follow-up shows that the CAR-T cell therapy Tecartus continues to elicit durable responses in patients with relapsed/refractory mantle cell lymphoma.

‘A New Benchmark’ Treatment Option for Older Patients with Mantle Cell Lymphoma

June 3rd 2022, 7:36pm

Article

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

Trial Launches to Study a New Drug for B-Cell Malignancies

May 20th 2022, 7:00pm

Article

NX-5948 may be able to pass through the blood-brain barrier in patients with B-cell malignancies, potentially making it a promising option for patients with disease in their central nervous system.

'Death Doulas' Help Patients With Cancer Face Their End of Life With Courage and Meaning

May 18th 2022, 7:00pm

Article

Dying does not have the be scary, and there are resources available to help patients and their loved ones, explained an expert.

Two-Drug Combo Elicits Similar Outcomes to Standard of Care in Young Patients With Non-Hodgkin Lymphoma

May 11th 2022, 9:00pm

Article

The use of bendamustine and Rituxan plus autologous stem cell transplantation and maintenance Rituxan resulted in similar outcomes to other Rituxan-based regimens that are currently the standard of care for young patients with mantle cell lymphoma, a type of non-Hodgkin lymphoma, who are eligible for transplant.